Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.

Plum, Patrick S; Hess, Timo; Bertrand, Denis; Morgenstern, Isabelle; Velazquez Camacho, Oscar; Jonas, Christoph; Alidousty, Christina; Wagner, Britta; Roessler, Stephanie; Albrecht, Thomas; Becker, Jessica; Richartz, Vanessa; Holz, Barbara; Hoppe, Sascha; Poh, Huay Mei; Chia, Burton Kuan Hui; Chan, Cheryl Xueli; Pathiraja, Thushangi; Teo, Audrey Sm; Marquardt, Jens U; ... (2024). Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker. Clinical and translational medicine, 14(6) Wiley 10.1002/ctm2.1723

Preview

Text Clinical___Translational_Med_-_2024_-_Plum_-_Integrative_genomic_analyses_of_European_intrahepatic_cholangiocarcinoma_.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (6MB) | Preview

BACKGROUND

Cholangiocarcinoma (CCA) is a fatal cancer of the bile duct with a poor prognosis owing to limited therapeutic options. The incidence of intrahepatic CCA (iCCA) is increasing worldwide, and its molecular basis is emerging. Environmental factors may contribute to regional differences in the mutation spectrum of European patients with iCCA, which are underrepresented in systematic genomic and transcriptomic studies of the disease.

METHODS

We describe an integrated whole-exome sequencing and transcriptomic study of 37 iCCAs patients in Germany.

RESULTS

We observed as most frequently mutated genes ARID1A (14%), IDH1, BAP1, TP53, KRAS, and ATM in 8% of patients. We identified FGFR2::BICC1 fusions in two tumours, and FGFR2::KCTD1 and TMEM106B::ROS1 as novel fusions with potential therapeutic implications in iCCA and confirmed oncogenic properties of TMEM106B::ROS1 in vitro. Using a data integration framework, we identified PBX1 as a novel central regulatory gene in iCCA. We performed extended screening by targeted sequencing of an additional 40 CCAs. In the joint analysis, IDH1 (13%), BAP1 (10%), TP53 (9%), KRAS (7%), ARID1A (7%), NF1 (5%), and ATM (5%) were the most frequently mutated genes, and we found PBX1 to show copy gain in 20% of the tumours. According to other studies, amplifications of PBX1 tend to occur in European iCCAs in contrast to liver fluke-associated Asian iCCAs.

CONCLUSIONS

By analyzing an additional European cohort of iCCA patients, we found that PBX1 protein expression was a marker of poor prognosis. Overall, our findings provide insight into key molecular alterations in iCCA, reveal new targetable fusion genes, and suggest that PBX1 is a novel modulator of this disease.

Interest & Impact

Downloads

0 since deposited on 17 Jun 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item